Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

Evropska unija - slovenščina - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklidno slikanje - terapevtski radiofarmacevtiki - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Evropska unija - slovenščina - EMA (European Medicines Agency)

roche registration gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell - antineoplastična sredstva - mabthera je navedeno v odraslih za naslednje indikacije:ne‑hodgkinova limfomi (nhl)mabthera je primerna za zdravljenje predhodno nezdravljenih odraslih bolnikov z faza iii‑iv folikularni limfom v kombinaciji s kemoterapijo. mabthera vzdrževanje terapija je primerna za zdravljenje odraslih, folikularni limfom bolniki odzivajo na indukcijsko zdravljenje. mabthera monotherapy je indiciran za zdravljenje odraslih bolnikov z faza iii‑iv folikularni limfom, ki so chemoresistant ali so v drugi ali poznejši ponovitve po kemoterapijo. mabthera je indiciran za zdravljenje odraslih bolnikov s cd20 pozitivni razpršenih velika b celic non‑hodgkinova limfom v kombinaciji z chop (ciklofosfamid, doxorubicin, vincristine, prednizolon) kemoterapijo. mabthera v kombinaciji s kemoterapijo je primerna za zdravljenje pediatričnih bolnikih (starih ≥ 6 mesecev do < 18 let) s predhodno nezdravljenih napredni fazi cd20 pozitivni razpršenih veliko b-celični limfom (dlbcl), burkitt limfom (bl)/burkitt levkemijo (mature b-celic akutno levkemijo) (bal) ali burkitt-kot so limfom (bll). kronično limfocitno levkemijo (cll)mabthera v kombinaciji s kemoterapijo je indiciran za zdravljenje bolnikov z predhodno nezdravljenih in relapsed/ognjevzdržni cll. samo omejeni so na voljo podatki o učinkovitosti in varnosti za bolnike predhodno zdravljenih z monoklonalna protitelesa, vključno z mabthera ali bolniki, ognjevzdržni, da prejšnji mabthera plus kemoterapijo. revmatoidni arthritismabthera v kombinaciji z metotreksatom je indiciran za zdravljenje odraslih bolnikov s hudo aktivnega revmatoidnega artritisa, ki so imeli z neustreznim odzivom ali nestrpnosti do drugih bolezni spreminjajo anti‑revmatičnih zdravila (dmard) vključno z enim ali več tumor nekroze faktor (tnf) inhibitor terapije. mabthera je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x‑ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. granulomatosis z polyangiitis in mikroskopsko polyangiitismabthera, v kombinaciji z glucocorticoids, je indicirano za zdravljenje odraslih bolnikov s hudo, aktivno granulomatosis z polyangiitis (wegener je) (gpa) in mikroskopsko polyangiitis (mpa). mabthera v kombinaciji z glucocorticoids, je primerna za indukcijo remisije pri pediatričnih bolnikih (starih ≥ 2 < 18 let) s hudo, aktivno gpa (wegener je) in mpa. pemphigus vulgarismabthera je indiciran za zdravljenje bolnikov z zmerno do hudo pemphigus vulgaris (pv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmathen s.a. - fluvastatin - tableta s podaljšanim sproščanjem - fluvastatin 80 mg / 1 tableta - fluvastatin

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hidroklorid - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

Evropska unija - slovenščina - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - druga zdravila na živčnem sistemu - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - vsi drugi terapevtski izdelki - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.